Skip to content
Review Open access

Prostate-directed Radiotherapy in Selected Patients With Metastatic Castration-sensitive Prostate Cancer: A Real-world Case Series

Oct 2026 · In Vivo · Vol 40, pp. 3843 - 3853 · 0 citations · 9 references
Medicine

TL;DR

In this small, highly selected cohort of patients demonstrating favorable initial responses to systemic therapy, prostate-directed RT was feasible and well tolerated, with no grade ≥2 acute RT-related toxicity, no late toxicity among evaluable patients, and no local events.

Abstract

Background/Aim: Prostate-directed radiotherapy (RT) improves outcomes in selected patients with metastatic castration-sensitive prostate cancer (mCSPC), particularly those with low metastatic burden. However, real-world information regarding its use after response to systemic therapy remains limited. This study describes the treatment characteristics, safety, and clinical course of selected patients with mCSPC who received prostate-directed RT. Patients and Methods: We retrospectively reviewed an institutional RT database containing 396 patients who initiated prostate-directed RT between April 2015 and March 2026. Thirteen patients had mCSPC at RT initiation and were included. Prostate-directed RT was considered after a marked prostate-specific antigen (PSA) decline and confirmation of no radiographic progression during first-line systemic therapy; no prespecified PSA threshold was used. Patient characteristics, RT details, RT-related adverse events, and clinical outcomes after RT completion were evaluated. Results: Eight patients had low-volume and five had high-volume disease. The median interval from initiation of first-line systemic therapy to RT was 8.4 months. The median PSA decline before RT was 99.9% (interquartile range=98.9-99.9%), and the median PSA level before RT was 0.028 ng/ml. All patients received intensity-modulated RT, and residual metastatic lesions were included in the RT target volume in six patients. All patients completed RT. No grade ≥2 acute genitourinary or gastrointestinal toxicity was observed, and no late RT-related toxicity occurred among the 11 patients evaluable for late toxicity. During follow-up (median, 39.6 months) after RT, four patients developed castration-resistant disease and four experienced radiographic progression. No post-RT local events or prostate cancer-specific deaths occurred; one patient died of an unrelated cause. Conclusion: In this small, highly selected cohort of patients demonstrating favorable initial responses to systemic therapy, prostate-directed RT was feasible and well tolerated, with no grade ≥2 acute RT-related toxicity, no late toxicity among evaluable patients, and no local events. Comparative efficacy cannot be determined because of the retrospective design, small sample size, and absence of a non-RT control group.

Read PDF

Similar papers

Oct 2026

Progression to castration-resistance and metastatic disease following androgen deprivation therapy for biochemical recurrence after prostate cancer surgery.

In this large national cohort of men with biochemical recurrence after surgery, most did not develop metastatic disease during nearly 10 years of follow up and one in four patients were treated with androgen deprivation therapy.

G. Raster, David A. Elliott, Ellen Hu et al. · 0 citations
Open access Oct 2026

Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined....

Ebru Karcı, T. Atasever, Tansel Çakır et al. · 0 citations
Open access Oct 2026

Real-World PSA Response and Safety Outcomes of 177Lu-PSMA-617 in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Validation Study

Background/Objectives: 177Lu-PSMA-617 is an established standard-of-care treatment for eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Treatment schedules and follow-up in routine practice may differ from clinical trial protocols. Post-a...

Jin Hyeok Choi, Chang Gon Kim, K. T. Oh et al. · 0 citations
Open access Oct 2026

Repeated metastasis-directed radiotherapy in patients with oligorecurrent prostate cancer: outcomes and risk stratification from a large multinational PSMA PET-guided cohort.

BACKGROUND AND PURPOSE Repeated metastasis-directed radiotherapy (MDRT) is increasingly used in patients with metachronous oligometastatic prostate cancer. However, the efficacy and optimal patient selection criteria remain insufficiently defined. MATERIAL AND METHODS Within the multinational PORTAL consortium, we ev...

R. van der Walle, Tessa D. van Bergen, Marcin Miszczyk et al. · 0 citations
Sep 2026

Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer.

Metastasis-directed external beam radiation therapy (EBRT) delivered for limited-volume disease, integrated with systemic radioligand therapy, may improve long-term disease control across the spectrum of metastatic prostate cancer. We examined 88 patients with metastatic prostate cancer who received both lutetium-177 P...

E. Adib, Emerson Lee, Yu-Hui Chen et al. · 0 citations
Review Open access Sep 2026

Treatment patterns and clinical outcomes among patients with metastatic castration-resistant prostate cancer: a multinational retrospective medical record review.

In a population where few had received treatment intensification for metastatic hormone-sensitive prostate cancer, real-world outcomes were aligned with those observed previously and in clinical trials, however, there remains significant need to broaden access to effective systemic therapy in mCRPC and to find new trea...

Robert J. Jones, Katherine Houghton, A. Niyazov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.